ERRATUM

Erratum to: NK cell-mediated antibody-dependent cellular cytotoxicity is enhanced by tamoxifen in HER2/neu non-amplified, but not HER2/neu-amplified, breast cancer cells

John O. Richards^{1,2,4} · Alex J. Albers^{1,2} · Thomas S. Smith^{1,2} · Judy A. Tjoe^{2,3}

Published online: 1 October 2016
© Springer-Verlag Berlin Heidelberg 2016

Erratum to: Cancer Immunol Immunother DOI 10.1007/s00262-016-1885-7

The authors incorrectly labeled the x-axis of Fig. 6c in the original publication. It should be labeled as shown in the corrected version below.

The online version of the original article can be found under doi: [10.1007/s00262-016-1885-7](https://doi.org/10.1007/s00262-016-1885-7).

✉ John O. Richards
john.richards@aurora.org

¹ Immunotherapy Research Laboratory, Aurora St. Luke's Medical Center, Aurora Health Care, Milwaukee, WI, USA

² Aurora Research Institute, Aurora Health Care, Milwaukee, WI, USA

³ Surgical Breast Oncology, Aurora Cancer Care, Aurora Health Care, Milwaukee, WI, USA

⁴ Immunology Research Laboratory, Aurora Research Institute, 960 N. 12th Street, 3rd Floor, Milwaukee, WI 53233, USA

Fig. 6 Reduction in CD16 is equal between 4OHT treated and untreated BT474. NK cells and BT474 were evaluated for FcγRIIIa and HER2/neu, respectively. **a** ABC values of HER2/neu on BT474. **b** ABC values of FcγRIIIa on NK cells. **c** Ratio of FcγRIIIa/HER2/neu